drug
vancomycin hydrochloride
Marketedupdated 6mo agoby Samson Medical Technologies LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 5all catalysts(0)
nothing on the calendar yet
Trials studying vancomycin hydrochloride
- phase2Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)
- phase2A Phase 2b Study to Evaluate the Efficacy, Safety, and PK Profiles of TNP-2092 Administered Via IA Injection in PJI Participants
- phase2A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants
- phase2Abbreviated Protocol for Two-Stage Exchange
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 13, 2035
~8.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (56)
- Nov 6, 2035formulationUS 10039804
- Nov 6, 2035formulationUS 10039804
- Nov 6, 2035formulationUS 10039804
- Nov 6, 2035formulationUS 10039804
- Nov 6, 2035formulationUS 10039804
- Nov 6, 2035formulationUS 10039804
- Nov 6, 2035formulationUS 10039804
- Nov 6, 2035formulationUS 10188697
- Nov 6, 2035formulationUS 10188697
- Nov 6, 2035formulationUS 10188697
- Nov 6, 2035formulationUS 10188697
- Nov 6, 2035formulationUS 10188697
- Nov 6, 2035formulationUS 10188697
- Nov 6, 2035formulationUS 10188697
- Nov 6, 2035formulationUS 10849956
- Nov 6, 2035formulationUS 10849956
- Nov 6, 2035formulationUS 10849956
- Nov 6, 2035formulationUS 10849956
- Nov 6, 2035formulationUS 10849956
- Nov 6, 2035formulationUS 10849956
- Nov 6, 2035formulationUS 10849956
- Nov 6, 2035method-of-use (U-282)US 11517609
- Nov 6, 2035method-of-use (U-282)US 11517609
- Nov 6, 2035method-of-use (U-282)US 11517609
- Nov 6, 2035method-of-use (U-282)US 11517609
- Nov 6, 2035method-of-use (U-282)US 11517609
- Nov 6, 2035method-of-use (U-282)US 11517609
- Nov 6, 2035method-of-use (U-282)US 11517609
- Nov 6, 2035formulationUS 11628200
- Nov 6, 2035formulationUS 11628200
- Nov 6, 2035formulationUS 11628200
- Nov 6, 2035formulationUS 11628200
- Nov 6, 2035formulationUS 11628200
- Nov 6, 2035formulationUS 11628200
- Nov 6, 2035formulationUS 11628200
- Nov 6, 2035formulationUS 12161690
- Nov 6, 2035formulationUS 12161690
- Nov 6, 2035formulationUS 12161690
- Nov 6, 2035formulationUS 12161690
- Nov 6, 2035formulationUS 12161690
- Nov 6, 2035formulationUS 12161690
- Nov 6, 2035formulationUS 12161690
- Mar 13, 2035formulationUS 10493028
- Mar 13, 2035formulationUS 10493028
- Mar 13, 2035formulationUS 10688046
- Mar 13, 2035formulationUS 10688046
- Mar 13, 2035formulationUS 10959946
- Mar 13, 2035formulationUS 10959946
- Mar 13, 2035formulationUS 10959947
- Mar 13, 2035formulationUS 10959947
- Mar 13, 2035formulationUS 10959948
- Mar 13, 2035formulationUS 10959948
- Mar 13, 2035formulationUS 10959949
- Mar 13, 2035formulationUS 10959949
- Mar 13, 2035formulationUS 11638692
- Mar 13, 2035formulationUS 11638692
News(1)
- Eugia US LLC (f/k/a Auro Medics Pharma LLC) Issues Voluntary Nationwide Recall of Vancomycin Hydrochloride for Injection USP 1.25g/Vial-30mL (Single Dose Vial) Due to Presence of Particulate MatterFOR IMMEDIATE RELEASE –November 06,2026 – East Windsor, New Jersey, Eugia US LLC (f/k/a Auro Medics Pharma LLC) is voluntarily recalling lot number 3VM26026A of Vancomycin Hydrochloride for Injecti…fda_recalls · 13d ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that